NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company specializing in nanomaterials for antiviral therapy, announced its participation in the D. Boral Capital Global Conference scheduled for May 7, 2026, at The Plaza Hotel in New York City. Anil R. Diwan, Ph.D., president and executive chairman, will hold one-on-one meetings with investors and interested parties from 9:45 a.m. to 2:45 p.m. ET. The full press release is available at https://ibn.fm/YxQyd.
The company’s lead drug candidate, NV-387, is a broad-spectrum antiviral designed to treat respiratory viral infections including RSV, COVID-19, Long COVID, and Influenza. NV-387 has also demonstrated effectiveness in animal models for Monkeypox (MPox), Smallpox, and Measles. This broad-spectrum potential positions NV-387 as a promising candidate in the fight against multiple viral threats, which is particularly relevant given the ongoing challenges posed by emerging viral diseases.
NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events. The company is now focused on advancing NV-387 into Phase II human clinical trials. The successful completion of Phase I without adverse events is a significant milestone, as it indicates a favorable safety profile, which is critical for further development.
In addition to NV-387, NanoViricides is developing NV-HHV-1 for the treatment of all Herpesvirus infections, including HSV-1 (cold sores), HSV-2 (genital ulcers), VZV (shingles), and chickenpox. However, the company cannot project an exact date for filing an Investigational New Drug (IND) application for any of its drugs due to dependence on external collaborators and consultants.
The D. Boral Capital Global Conference provides a platform for NanoViricides to engage with the investment community and discuss its pipeline and future plans. For investors, this event offers an opportunity to gain insights into the company's progress and strategic direction. The latest news and updates on NNVC are available in the company’s newsroom at https://ibn.fm/NNVC.
The implications of NanoViricides' participation in this conference are significant for the biotech and pharmaceutical industries. As the world continues to grapple with viral pandemics and the emergence of new viral strains, the development of broad-spectrum antivirals like NV-387 could provide a critical tool for public health. If NV-387 proves effective in Phase II trials, it could become a key therapeutic option for multiple respiratory viral infections, potentially reducing the burden on healthcare systems and improving patient outcomes.
Furthermore, the company's focus on nanomaterials for antiviral therapy represents a novel approach that could lead to more effective treatments with fewer side effects. For business leaders and investors, the progress of NanoViricides' drug candidates is a development to watch, as it could reshape the antiviral treatment landscape and offer substantial market opportunities.
